StoneX Group Inc. Makes New $544,000 Investment in Doximity, Inc. (NASDAQ:DOCS)

StoneX Group Inc. acquired a new position in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,182 shares of the company's stock, valued at approximately $544,000.

Several other institutional investors and hedge funds also recently bought and sold shares of DOCS. Global Retirement Partners LLC boosted its stake in Doximity by 468.1% in the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock worth $29,000 after purchasing an additional 440 shares during the period. UMB Bank n.a. raised its position in shares of Doximity by 69.1% during the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after buying an additional 235 shares in the last quarter. Larson Financial Group LLC increased its stake in Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after acquiring an additional 250 shares during the last quarter. Optimum Investment Advisors purchased a new stake in Doximity during the fourth quarter valued at about $43,000. Finally, Morse Asset Management Inc purchased a new position in shares of Doximity in the 3rd quarter worth about $46,000. 87.19% of the stock is owned by institutional investors.

Doximity Trading Up 1.4 %

DOCS stock traded up $0.70 during trading on Monday, reaching $51.94. The stock had a trading volume of 1,405,589 shares, compared to its average volume of 1,951,984. The firm has a market cap of $9.70 billion, a PE ratio of 51.92, a PEG ratio of 4.10 and a beta of 1.41. The stock's 50 day moving average is $65.50 and its two-hundred day moving average is $55.12. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21.

Remove Ads

Insider Buying and Selling

In other news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company's stock, valued at $366,463.20. The trade was a 75.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 37.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DOCS. The Goldman Sachs Group boosted their price objective on shares of Doximity from $58.00 to $80.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Leerink Partnrs raised shares of Doximity from a "hold" rating to a "strong-buy" rating in a report on Friday, February 7th. KeyCorp lowered their price target on Doximity from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC raised their target price on shares of Doximity from $65.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Leerink Partners upgraded shares of Doximity from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $60.00 to $90.00 in a report on Friday, February 7th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $64.22.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.